US Stock MarketDetailed Quotes

ANTX AN2 Therapeutics

Watchlist
  • 1.260
  • -0.010-0.79%
Close Dec 20 16:00 ET
  • 1.260
  • 0.0000.00%
Post 20:05 ET
37.65MMarket Cap-0.63P/E (TTM)

AN2 Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

AN2 Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
--2024/Q30.000 / 0.000--
--2024/Q20.000 / 0.000--
--2024/Q10.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
--2024/Q30.000 / 0.000--
--2024/Q20.000 / 0.000--
--2024/Q10.000 / 0.000--

Unlock Free Earnings Estimates

AN2 Therapeutics Earnings Reports

  • AN2 Therapeutics | 8-K: AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

    Nov 13 16:10 ET

  • AN2 Therapeutics | 10-Q: Q3 2024 Earnings Report

    Nov 13 16:08 ET

  • AN2 Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 13 16:21 ET

  • AN2 Therapeutics | 8-K: AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

    Aug 13 16:08 ET

    • Read more

    Trending US Stocks
    Best Growth Stocks Best Growth Stocks

    Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

    Symbol Mini Chart % Chg
    Ermenegildo Zegna NV
    ZGN
    +6.16%
    DexCom
    DXCM
    +5.57%
    New Fortress Energy
    NFE
    +5.37%
    Workday
    WDAY
    +2.33%
    eBay
    EBAY
    +1.66%

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Dec 21, 2024

    Buy

    • Buy

      33.33%

    • Hold

      66.67%

    • Sell

      0.00%

    Price Target

    No Data